KR102077876B1 - Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물 - Google Patents

Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물 Download PDF

Info

Publication number
KR102077876B1
KR102077876B1 KR1020147036531A KR20147036531A KR102077876B1 KR 102077876 B1 KR102077876 B1 KR 102077876B1 KR 1020147036531 A KR1020147036531 A KR 1020147036531A KR 20147036531 A KR20147036531 A KR 20147036531A KR 102077876 B1 KR102077876 B1 KR 102077876B1
Authority
KR
South Korea
Prior art keywords
peptide
formula
hiv
crm197
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147036531A
Other languages
English (en)
Korean (ko)
Other versions
KR20150032266A (ko
Inventor
조엘 크루즈
총 팡 라파엘 호
도미니끄 데스퐁뗀느
Original Assignee
앵나비르박스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앵나비르박스 filed Critical 앵나비르박스
Publication of KR20150032266A publication Critical patent/KR20150032266A/ko
Application granted granted Critical
Publication of KR102077876B1 publication Critical patent/KR102077876B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020147036531A 2012-05-31 2013-05-30 Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물 Active KR102077876B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305602.0 2012-05-31
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (2)

Publication Number Publication Date
KR20150032266A KR20150032266A (ko) 2015-03-25
KR102077876B1 true KR102077876B1 (ko) 2020-02-14

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147036531A Active KR102077876B1 (ko) 2012-05-31 2013-05-30 Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물

Country Status (21)

Country Link
US (1) US9511136B2 (https=)
EP (2) EP2668959B1 (https=)
JP (1) JP6352251B2 (https=)
KR (1) KR102077876B1 (https=)
CN (1) CN104507496B (https=)
AU (1) AU2013269120B2 (https=)
BR (1) BR112014029861B1 (https=)
CA (1) CA2875162C (https=)
DK (1) DK2668959T3 (https=)
EA (1) EA027803B1 (https=)
ES (2) ES2528109T3 (https=)
HR (1) HRP20150058T1 (https=)
IN (1) IN2014DN10128A (https=)
MX (1) MX360206B (https=)
PL (1) PL2668959T3 (https=)
PT (1) PT2668959E (https=)
RS (1) RS53769B1 (https=)
SI (1) SI2668959T1 (https=)
UA (1) UA118542C2 (https=)
WO (1) WO2013179262A1 (https=)
ZA (1) ZA201409023B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
TWI740823B (zh) * 2015-04-17 2021-10-01 澳大利亞商保健樂科技昆士蘭有限公司 疫苗組成物及其用途
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
EP2336147B1 (en) * 2003-12-17 2014-04-30 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecular Medicine Reports, Vol. 4, No. 5, pp. 857-863(2011.09.)*
PNAS, Vol. 105, No. 6, pp. 2100-2104(2008.02.12.)

Also Published As

Publication number Publication date
PT2668959E (pt) 2015-02-05
IN2014DN10128A (https=) 2015-08-21
EP2854846A1 (en) 2015-04-08
UA118542C2 (uk) 2019-02-11
US20150147348A1 (en) 2015-05-28
MX2014014526A (es) 2015-06-02
BR112014029861A2 (pt) 2017-07-25
EP2854846B1 (en) 2018-09-12
ES2701084T3 (es) 2019-02-20
US9511136B2 (en) 2016-12-06
ZA201409023B (en) 2016-08-31
ES2528109T3 (es) 2015-02-04
AU2013269120A1 (en) 2014-12-18
WO2013179262A1 (en) 2013-12-05
CN104507496A (zh) 2015-04-08
AU2013269120B2 (en) 2017-04-20
MX360206B (es) 2018-10-24
CA2875162C (en) 2021-09-14
JP2015519359A (ja) 2015-07-09
SI2668959T1 (sl) 2015-03-31
PL2668959T3 (pl) 2015-04-30
KR20150032266A (ko) 2015-03-25
EP2668959B1 (en) 2014-11-05
JP6352251B2 (ja) 2018-07-04
BR112014029861B1 (pt) 2022-05-24
RS53769B1 (sr) 2015-06-30
CA2875162A1 (en) 2013-12-05
CN104507496B (zh) 2018-08-03
EP2668959A1 (en) 2013-12-04
EA201491969A1 (ru) 2015-04-30
DK2668959T3 (en) 2015-01-26
EA027803B1 (ru) 2017-09-29
HRP20150058T1 (hr) 2015-04-10

Similar Documents

Publication Publication Date Title
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
KR102077876B1 (ko) Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물
CA2793087C (en) Peptides, conjugates and method for increasing immunogenicity of a vaccine
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
SK362692A3 (en) Expression of specific immunogens by using of virus antigene
US12397050B2 (en) Universal mammalian influenza vaccine
CN105377876A (zh) 免疫原性肽缀合物及以之诱导抗流感治疗性抗体应答的方法
JP2010500407A (ja) Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
JP2003533542A (ja) Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
EA048154B1 (ru) Иммуногенные соединения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141226

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180420

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190410

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190610

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180420

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150105

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20191219

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20191122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190610

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180420

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150105

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200210

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240213

Start annual number: 5

End annual number: 5